Risk of Violating the Fair Competition Code for the Medical Device Industry
First written in FY2022. 6 of 7 entries say "Restated". Latest entry: FY2025-H1.
2 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period under review, there were no significant changes in the matters described in this interim report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It states that there have been no material changes in the risk of violating the Fair Competition Code for the Medical Devices Industry. - FY2024RestatedAnnual report
「Our Group complies with the Fair Competition Code for the Medical Devices Industry in its sales activities and works to educate and raise awareness among employees. However, if differences in interpretation arise with the authorities in the future and the Group violates the Fair Competition Code for the Medical Devices Industry, it may be found to have violated the Act against Unjustifiable Premiums and Misleading Representations and may be subject to penalties such as fines.」
Continues to identify as a compliance risk the possibility that violations of the Fair Competition Code for the Medical Device Industry could lead to violations of the Act against Unjustifiable Premiums and Misleading Representations, penalties and other consequences. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It states that there have been no material changes in the risk of violating the Fair Competition Code for the Medical Devices Industry. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes in the risk of violating the Fair Competition Code for the Medical Devices Industry. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It states that there have been no material changes in the risk of violating the Fair Competition Code for the Medical Devices Industry. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes in the risk of violating the Fair Competition Code for the Medical Devices Industry. - FY2022First statedAnnual report
「Our Group complies with the Fair Competition Code for the Medical Devices Industry in its sales activities and works to educate and raise awareness among employees. However, if differences in interpretation arise with the authorities in the future and the Group violates the Fair Competition Code for the Medical Devices Industry, it may be found to have violated the Act against Unjustifiable Premiums and Misleading Representations and may be subject to penalties such as fines.」
The company has identified as a new compliance risk the possibility that violations of the Fair Competition Code for the Medical Device Industry could lead to violations of the Act against Unjustifiable Premiums and Misleading Representations, penalties and other consequences.